A Cochrane review [Abstract] 1 included 17 studies with a total of 1 817 subjects. The medical interventions included octreotide (10 studies), somatostatin (5 studies), terlipressin (1 study) and vasopressin (1 study). No significant differences were found comparing sclerotherapy with each vasoactive drug for any outcome. Combining all the trials irrespective of the vasoactive drug, the risk differences were for failure to control bleeding (16 RCTs) -0.02 (95% CI -0.06 to 0.02), five-day failure rate (9 RCTs) -0.05 (95% CI -0.10 to 0.01), rebleeding (16 RCTs) 0.01 (95% CI -0.03 to 0.05), and mortality (17 RCTs) -0.02 (95% CI -0.06 to 0.02). Adverse events (RD 0.08, 95% CI 0.03 to 0.14; 12 studies) and serious adverse events (RD 0.05, 95% CI 0.02 to 0.08; 5 studies) were significantly more frequent with sclerotherapy.
Primary/Secondary Keywords